Corporate Corruption News ArticlesExcerpts of key news articles on corporate corruption
How much influence do private networks of the rich and powerful have on government policies and international relations? One group, the Bilderberg, has often attracted speculation that it forms a shadowy global government. Every year since 1954 [they have brought] together about 120 leading business people and politicians. At this year's meeting in Germany, the audience included the heads of the World Bank and European Central Bank, Chairmen or Chief Executives from Nokia, BP, Unilever, DaimlerChrysler and Pepsi ... editors from five major newspapers, members of parliament, ministers, European commissioners ... and the queen of the Netherlands. The chairman ... is 73-year-old Viscount Etienne Davignon. In an extremely rare interview, he played down the importance of Bilderberg. "I don't think (we are) a global ruling class because I don't think a global ruling class exists." Will Hutton ... who attended a Bilderberg meeting in 1997, says people take part in these networks in order to influence the way the world works, to create what he calls "the international common sense". And that "common sense" is one which supports the interests of Bilderberg's main participants. For Bilderberg's critics the fact that there is almost no publicity about the annual meetings is proof that they are up to no good. Bilderberg meetings often feature future political leaders shortly before they become household names. Bill Clinton went in 1991 while still governor of Arkansas, Tony Blair was there two years later while still an opposition MP. All the recent presidents of the European Commission attended Bilderberg meetings before they were appointed. Informal and private networks like Bilderberg have helped to oil the wheels of global politics and globalisation for the past half a century.
Note: Why is this meeting of top world leaders kept so secret? Why, until a few years ago, was there virtually no reporting on this influential group in the major media? Thankfully, the alternative media has had some good articles. And a Google search can be highly informative. Explore many other revealing major media news articles on powerful secret societies. And for those interested, check out reliable, eye-opening information covering the big picture of how and why these secret societies are using government-sponsored mind control programs to achieve their agenda.
There are no magic bullets in the fight against cancer: that's the first thing every responsible scientist mentions when discussing a possible new treatment, no matter how promising. If there were a magic bullet, though, it might be something like dichloroacetate, or DCA, a drug that kills cancer cells by exploiting a fundamental weakness found in a wide range of solid tumors. So far, though, it kills them just in test tubes and in rats infected with human cancer cells; it has never been tested against cancer in living human beings. DCA ... is an existing drug whose side effects are well-studied and relatively tolerable. Also, it's a small molecule that might be able to cross the blood-brain barrier to reach otherwise intractable brain tumors. Within days after a technical paper on DCA appeared in the journal Cancer Cell last week, the lead author, Dr. Evangelos Michelakis of the University of Alberta, was deluged with calls and e-mails from prospective patients—to whom he can say only, “Hang in there.” DCA is a remarkably simple molecule. It acts in the body to promote the activity of the mitochondria. Researchers have assumed that the mitochondria in cancer cells were irreparably damaged. But Michelakis wondered if that was really true. With his colleagues he used DCA to turn back on the mitochondria in cancer cells—which promptly died. One of the great things about DCA is that it's a simple compound, in the public domain, and could be produced for pennies a dose. But that's also a problem, because big drug companies are unlikely to spend a billion dollars or so on large-scale clinical trials for a compound they can't patent.
Note: Read a 2010 follow-up by Dr. Michelakis with promising results and watch a 10-minute video. Explore the DCA website. Why didn't other mass media report this major story? Why aren't many millions of dollars being poured into research? Notice even Newsweek acknowledges the drug companies are not interested in finding a cure for cancer if they can't make a profit from it. Some suspect the drug companies have even suppressed cancer cures found in the past. See one amazing example of this. For more, see these major media articles on potential cancer cures.
Some of the world's biggest, most profitable corporations enjoy a far lower tax rate than you do – that is, if they pay taxes at all. The most egregious example is General Electric. Last year the conglomerate generated $10.3 billion in pretax income, but ended up owing nothing to Uncle Sam. In fact, it recorded a tax benefit of $1.1 billion. How did this happen? It's complicated. GE in effect consists of two divisions: General Electric Capital and everything else. The everything else – maker of engines, power plants, TV shows and the like – would have paid a 22% tax rate if it was a standalone company. It's GE Capital that keeps the overall tax bill so low. Over the last two years, GE Capital has displayed an uncanny ability to lose lots of money in the U.S. (posting a $6.5 billion loss in 2009), and make lots of money overseas (a $4.3 billion gain). Not only do the U.S. losses balance out the overseas gains, but GE can defer taxes on that overseas income indefinitely. It's the tax benefit of overseas operations that is the biggest reason why multinationals end up with lower tax rates than the rest of us.
Note: Forbes later changed the title of this article to a more innocuous "What The Top U.S. Companies Pay In Taxes." Can you believe that GE not only pays no taxes, they actually get credit from the US government? They ship US jobs overseas and then reap huge tax benefits as a result. What's wrong with this picture? For a wealth of media news articles on the hidden manipulations of major financial corporations, click here.
If you follow the news about health research, you risk whiplash. First garlic lowers bad cholesterol, then—after more study—it doesn’t. Hormone replacement reduces the risk of heart disease in postmenopausal women, until a huge study finds that it doesn’t. But what if wrong answers aren’t the exception but the rule? More and more scholars who scrutinize health research are now making that claim. It isn’t just an individual study here and there that’s flawed, they charge. Instead, the very framework of medical investigation may be off-kilter, leading time and again to findings that are at best unproved and at worst dangerously wrong. The result is a system that leads patients and physicians astray—spurring often costly regimens that won’t help and may even harm you. Even a cursory glance at medical journals shows that once heralded studies keep falling by the wayside. A major study concluded there’s no good evidence that statins (drugs like Lipitor and Crestor) help people with no history of heart disease. The study ... was based on an evaluation of 14 individual trials with 34,272 patients. Cost of statins: more than $20 billion per year. “Positive” drug trials, which find that a treatment is effective, and “negative” trials, in which a drug fails, take the same amount of time to conduct. But negative trials took an extra two to four years to be published. With billions of dollars on the line, companies are loath to declare a new drug ineffective. As a result of the lag in publishing negative studies, patients receive a treatment that is actually ineffective. From clinical trials of new drugs to cutting-edge genetics, biomedical research is riddled with incorrect findings.
Note: For the good of your health, the entire article at the link above is well worth reading. For lots more on how the profit-oriented health profession puts public health at risk, click here and here.
After receiving billions in aid from U.S. taxpayers, the nation's largest banks say they can't track exactly how they're spending it. Some won't even talk about it. "We're choosing not to disclose that," said Kevin Heine, spokesman for Bank of New York Mellon, which received about $3 billion. The Associated Press contacted 21 banks that received at least $1 billion in government money and asked four questions: How much has been spent? What was it spent on? How much is being held in savings, and what's the plan for the rest? None of the banks provided specific answers. Some banks said they simply didn't know where the money was going. There has been no accounting of how banks spend that money. The answers highlight the secrecy surrounding the Troubled Asset Relief Program, which earmarked $700 billion ... to help rescue the financial industry. Lawmakers summoned bank executives to Capitol Hill last month and implored them ... not to hoard it or spend it on corporate bonuses, junkets or to buy other banks. But there is no process in place to make sure that's happening and there are no consequences for banks that don't comply. Meanwhile, banks that are getting taxpayer bailouts awarded their top executives nearly $1.6 billion in salaries, bonuses, and other benefits last year. Congress attached nearly no strings to the $700 billion bailout in October. And the Treasury Department, which doles out the money, never asked banks how it would be spent. No bank provided even the most basic accounting for the federal money. Most banks wouldn't say why they were keeping the details secret.
Note: Explore key information that the bankers don't want you to know on the Federal Reserve, which is neither federal, nor a reserve. For more along these lines, see concise summaries of deeply revealing news articles on the banking bailout from reliable major media sources. Then explore the excellent, reliable resources suggesting major corruption provided in our Banking Information Center.
They're some of the most trusted voices in the defense of vaccine safety: the American Academy of Pediatrics, Every Child By Two, and pediatrician Dr. Paul Offit. But CBS News has found these three have something more in common - strong financial ties to the industry whose products they promote and defend. The vaccine industry gives millions to the Academy of Pediatrics for conferences, grants, medical education classes and even helped build their headquarters. The totals are kept secret, but public documents reveal bits and pieces. A $342,000 payment from Wyeth, maker of the pneumococcal vaccine - which makes $2 billion a year in sales. A $433,000 contribution from Merck, the same year the academy endorsed Merck's HPV vaccine - which made $1.5 billion a year in sales. Every Child By Two, a group that promotes early immunization for all children, admits the group takes money from the vaccine industry, too - but wouldn't tell us how much. Then there's Paul Offit, perhaps the most widely-quoted defender of vaccine safety. He's gone so far as to say babies can tolerate "10,000 vaccines at once." In fact, he's a vaccine industry insider. Offit holds a $1.5 million dollar research chair at Children's Hospital, funded by Merck. He holds the patent on an anti-diarrhea vaccine he developed with Merck. And future royalties for the vaccine were just sold for $182 million cash.
Note: An excellent report endorsed by many respected doctors and nurses reveals the serious risks of vaccines. Read an incisive list of questions regarding vaccines that are rarely raised by the media. The report accessible on this US government webpage states, "Since 1988, over 24,200 petitions have been filed with the VICP [Vaccine Injury Compensation Program] ... with 8,162 of those determined to be compensable. Total compensation paid over the life of the program is approximately $4.5 billion." Why isn't that huge price tag for vaccine injuries being talked about?
Goldman Sachs analysts attempted to address a touchy subject for biotech companies, especially those involved in the pioneering "gene therapy" treatment: cures could be bad for business in the long run. "Is curing patients a sustainable business model?" analysts ask in an April 10 report entitled "The Genome Revolution." "The potential to deliver 'one shot cures' is one of the most attractive aspects of gene therapy, genetically-engineered cell therapy and gene editing. However, such treatments offer a very different outlook with regard to recurring revenue versus chronic therapies," analyst Salveen Richter wrote in the note to clients. "While this proposition carries tremendous value for patients and society, it could represent a challenge for genome medicine developers looking for sustained cash flow." Richter cited Gilead Sciences' treatments for hepatitis C, which achieved cure rates of more than 90 percent. The company's U.S. sales for these hepatitis C treatments peaked at $12.5 billion in 2015, but have been falling ever since. "GILD is a case in point, where the success of its hepatitis C franchise has gradually exhausted the available pool of treatable patients," the analyst wrote. "In the case of infectious diseases such as hepatitis C, curing existing patients also decreases the number of carriers able to transmit the virus to new patients, thus the incident pool also declines. Where an incident pool remains stable (eg, in cancer) the potential for a cure poses less risk to the sustainability of a franchise."
Note: Many cancer treatments have been suppressed, sometimes in brutal ways, because the medical profession would lose the huge profits of traditional cancer treatments. Watch this video for undeniable evidence showing that this is the case. Read an excellent article on how the profiteering drug industry is crippling our children, possibly even intentionally. For more along these lines, see concise summaries of deeply revealing health news articles from reliable major media sources.
Many critical election systems in the United States are poorly secured and protected against malicious attacks. In the 15 years since electronic voting machines were first adopted by many states, numerous reports by computer scientists have shown nearly every make and model to be vulnerable to hacking. The systems were not initially designed with robust security in mind, and even where security features were included, experts have found them to be poorly implemented with glaring holes. But for as long as experts have warned about security problems, voting machine makers and election officials have denied that the machines can be remotely hacked. Election officials also assert that routine procedures they perform would detect if someone altered transmitted votes or machine software. Experts, however, say ... that vendor claims about security can’t be trusted. "Vendors have absolutely fumbled every single attempt in security," says Jacob D. Stauffer, vice president of operations for Coherent Cyber, who has conducted voting-machine security assessments for California’s secretary of state for a decade. Stauffer and colleagues ... found the voting machines and election-management systems to be rife with security problems. Attackers could theoretically intercept unofficial results as they’re transmitted on election night — or, worse, use the modem connections to reach back into election machines at either end and install malware or alter election software and official results.
Note: For more along these lines, see concise summaries of deeply revealing elections corruption news articles from reliable major media sources. Then explore the excellent, reliable resources provided in our Elections Information Center.
Merck made a "hit list" of doctors who criticized Vioxx, according to testimony in a Vioxx class action case in Australia. According to The Australian, Merck emails from 1999 showed company execs complaining about doctors who disliked using Vioxx. The list, emailed between Merck employees, contained doctors' names with the labels "neutralise," "neutralised" or "discredit" next to them. One email said: We may need to seek them out and destroy them where they live. The plaintiffs' lawyer gave this assessment: "It gives you the dark side of the use of key opinion leaders and thought leaders. If (they) say things you don't like to hear, you have to neutralise them." The court was told that James Fries, professor of medicine at Stanford University, wrote to the then Merck head Ray Gilmartin in October 2000 to complain about the treatment of some of his researchers who had criticised the drug. "Even worse were allegations of Merck damage control by intimidation," he wrote. "This has happened to at least eight (clinical) investigators. I was mildly threatened myself, but I never have spoken or written on these issues." The allegations come on the heels of revelations that Merck created a fake medical journal -- the Australasian Journal of Bone and Joint Medicine -- in which to publish studies about Vioxx; had pop songs commissioned about Vioxx to inspire its staff, and paid ghostwriters to draft articles about the drug.
Note: FDA analysts estimated that Vioxx caused between 88,000 and 139,000 heart attacks, 30 to 40 percent of which were probably fatal, in the five years the drug was on the market. For more along these lines, see concise summaries of deeply revealing health corruption news articles from reliable major media sources.
We could make faster progress against cancer by changing the way drugs are developed. In the current system, if a promising compound can’t be patented, it is highly unlikely ever to make it to market — no matter how well it performs in the laboratory. The development of new cancer drugs is crippled as a result. The reason for this problem is that bringing a new drug to market is extremely expensive. In 2001, the estimated cost was $802 million; today it is approximately $1 billion. To ensure a healthy return on such staggering investments, drug companies seek to formulate new drugs in a way that guarantees watertight patents. In the meantime, cancer patients miss out on treatments that may be highly effective and less expensive to boot. In 2004, Johns Hopkins researchers discovered that an off-the-shelf compound called 3-bromopyruvate could arrest the growth of liver cancer in rats. The results were dramatic; moreover, the investigators estimated that the cost to treat patients would be around 70 cents per day. Yet, three years later, no major drug company has shown interest in developing this drug. The hormone melatonin, sold as an inexpensive food supplement in the United States, has repeatedly been shown to slow the growth of various cancers when used in conjunction with conventional treatments. Early this year, another readily available industrial chemical, dichloroacetate, was found by researchers at the University of Alberta to shrink tumors in laboratory animals by up to 75 percent. However ... dichloroacetate is not patentable, and the lead researcher is concerned that it may be difficult to find funding from private investors to test the chemical. Potential anticancer drugs should be judged on their scientific merit, not on their patentability.
Note: To explore several cancer cures which have shown dramatic potential, yet are not being studied for lack of funds due to inability to patent the process, click here. Why are these very promising treatments not being fast-tracked as the expensive AIDS drugs were? For a top MD's revealing comments on this, click here. And for why the media won't feature these promising cancer treatments in headlines, click here.
In June 2000, a group of top government scientists and health officials gathered for a meeting at the isolated Simpsonwood conference center ... to ensure complete secrecy. The federal officials and industry representatives had assembled to discuss a disturbing new study that raised alarming questions about the safety of a host of common childhood vaccines administered to infants and young children. A mercury-based preservative in the vaccines -- thimerosal -- appeared to be responsible for a dramatic increase in autism. But instead of taking immediate steps to alert the public and rid the vaccine supply of thimerosal, the officials and executives at Simpsonwood spent most of the next two days discussing how to cover up the damaging data. According to transcripts obtained under the Freedom of Information Act, many at the meeting were concerned about how the damaging revelations about thimerosal would affect the vaccine industry's bottom line. The CDC paid the Institute of Medicine to conduct a new study to whitewash the risks of thimerosal, ordering researchers to "rule out" the chemical's link to autism. Senate Majority Leader Bill Frist, who has received $873,000 in contributions from the pharmaceutical industry, has been working to immunize vaccine makers from liability in 4,200 lawsuits that have been filed by the parents of injured children. More than 500,000 kids currently suffer from autism. The disease was unknown until 1943, when it was identified and diagnosed among 11 children born in the months after thimerosal was first added to baby vaccines in 1931. Internal documents reveal that Eli Lilly, which first developed thimerosal, knew from the start that its product could cause damage -- and even death -- in both animals and humans.
Note: A good, though somewhat watered down version of the above article was published in the Boston Globe on July 1, 2005. To see this article on the Globe website, click here. For an excellent report endorsed by dozens of respected doctors and nurses on the serious risks and dangers of vaccines, click here. Watch an excellent video of Emmy award winning reporter Sharyl Attkisson exposing how the government fired an vaccine expert who found links to autism.
Lockheed Martin doesn't run the United States. But it does help run a breathtakingly big part of it. Lockheed ... has built a formidable information-technology empire that now stretches from the Pentagon to the post office. It sorts your mail and totals your taxes. It cuts Social Security checks and counts the United States census. It runs space flights and monitors air traffic. Lockheed ... is best known for its weapons. But in the post-9/11 world, Lockheed has become more than just the biggest corporate cog in what Dwight D. Eisenhower called the military-industrial complex. It is increasingly putting its stamp on the nation's military policies. Former Lockheed executives, lobbyists and lawyers hold crucial posts at the White House and the Pentagon, picking weapons and setting policies. War and crisis have been good for business. The company's stock has tripled in the last four years. Lockheed is creating robot soldiers and neural software - "intelligent agents" - to do their work. Israel spends much of the $1.8 billion in annual military aid from the United States to buy F-16 warplanes from Lockheed. Its own executives say the concentration of power among military contractors is more intense than in any other sector of business outside banking. AND, after 9/11 ... cost is essentially irrelevant. Former Lockheed executives serve on the Defense Policy Board ... and the Homeland Security Advisory Council, which help make military and intelligence policy and pick weapons for future battles. Lockheed's board includes E. C. Aldridge Jr. ... the Pentagon's chief weapons buyer.
Note: If the above link fails, click here. To say that "war and crisis have been good for business" is quite an understatement. To read what one of the most highly decorated generals had to say about this, click here.
Marcia Angell [is] a faculty member at the Harvard Medical School [and one of the] former editors of The New England Journal of Medicine. Her new book, "The Truth About the Drug Companies," is a sober, clear-eyed attack on the excesses of drug company power. How does the drug industry deceive us? It plies attending physicians with expense-paid junkets to St. Croix and Key West, Fla., where they are given honoraria and consulting fees to listen to promotional presentations. It promotes new or little-known diseases such as "social anxiety disorder" and "premenstrual dysphoric disorder" as a way of selling the drugs that treat them. It sets up phony front groups disguised as "patient advocacy organizations." It hires ghostwriters to produce misleading scientific articles and then pays academic physicians to sign on as authors. It sends paid lackeys and shills out onto the academic lecture circuit to ''educate" doctors about a drug's unapproved uses. It hires multinational PR firms to trumpet dubious studies as scientific breakthroughs while burying the studies that are likely to harm sales. It buys up the results of publicly funded research. It maintains a political chokehold on the American public by donating more money to political campaigns than any other industry in the country. For many years the drug industry has reaped the highest profit margins of any industry in America. In 2002, the top 10 American drug companies had profit margins of 17 percent; Pfizer, the largest, had profit margins of 26 percent. So staggeringly profitable is the drug industry that in 2002 the combined profits for the top 10 drug companies in the Fortune 500 were greater than those of all the other 490 companies combined.
The Carlyle Group [is] an investment house famous as one of the most well-connected companies anywhere. Former president George H.W. Bush is a Carlyle adviser. Former British prime minister John Major heads its European arm. Former secretary of state James Baker is senior counselor, former White House budget chief Richard Darman is a partner, former SEC chairman Arthur Levitt is senior adviser -- the list goes on. Those associations have brought Carlyle enormous success. The Washington-based merchant bank controls nearly $14 billion in investments, making it the largest private equity manager in the world. It buys and sells whole companies the way some firms trade shares of stock. But the connections also have cost Carlyle. It has developed a reputation as the CIA of the business world -- omnipresent, powerful, a little sinister. Media outlets from the Village Voice to BusinessWeek have depicted Carlyle as manipulating the levers of government from shadowy back rooms. Congresswoman Cynthia McKinney (D-Ga.) even suggested that Carlyle's and Bush's ties to the Middle East made them somehow complicitous in the Sept. 11 terror attacks. It didn't help that as the World Trade Center burned on Sept. 11, 2001, the news interrupted a Carlyle business conference at the Ritz-Carlton Hotel here attended by a brother of Osama bin Laden. Former president Bush, a fellow investor, had been with him at the conference the previous day. Bush['s] primary function is to give speeches for Carlyle that attract wealthy foreigners in places where the former president is especially revered, such as Asia. The company has rewarded its faithful with a 36 percent average annual rate of return.
Note: If the above link fails, click here. To understand the amazingly powerful role of this low-profile, yet extremely wealthy and influential group, click here to view free a 48-minute documentary shown on Dutch national TV which clearly depicts the depths of corruption and deceit at the highest levels of government. You will be thankful that you watched this highly educational film.
Outside this country, there is a widespread belief that U.S. military deployments in Central Asia mostly are about oil. An article in the Guardian of London headlined, "A pro-western regime in Kabul should give the U.S. an Afghan route for Caspian oil," foreshadowed the kind of skeptical coverage the U.S. war now receives in many countries. Author George Monbiot ... wrote that the U.S. oil company Unocal Corp. had been negotiating with the Taliban since 1995 to build "oil and gas pipelines from Turkmenistan, through Afghanistan and into Pakistani ports on the Arabian sea." Unocal pulled out of the deal after the 1998 terrorist attacks on U.S. embassies in Kenya and Tanzania were linked to terrorists based in Afghanistan. The terrorist acts of Sept. 11, though tragic, provided the Bush administration a [pretext] to invade Afghanistan, oust the recalcitrant Taliban and, coincidentally, smooth the way for the pipeline. To make things even smoother, the U.S. engineered the rise to power of two former Unocal employees: Hamid Karzai, the new interim president of Afghanistan, and Zalmay Khalizad, the Bush administration's Afghanistan envoy. [Uri] Averny, a former member of the Israeli Knesset ... argues that the war on terrorism provides a perfect pretext for America's imperial interests. "If one looks at the map of the big American bases created for the war, one is struck by the fact that they are completely identical to the route of the projected oil pipeline to the Indian Ocean." No wonder the rest of the world is a bit skeptical about our war on evildoers.
Note: Why do so few people know that these two top officials of Afghanistan were once paid by an American oil company? For important reports from major media sources on the realities of the "war on terror," click here.
The International Federation of Health Plans, a group representing the C.E.O.s of health insurers worldwide, publishes a guide every few years on the international cost for common medical services. Its newest report, on 2017 prices, came out this month. Every time, the upshot is vivid and similar: For almost everything on the list, there is a large divergence between the United States and everyone else. Patients and insurance companies in the United States pay higher prices for medications, imaging tests, basic health visits and common operations. Those high prices make health care in the U.S. extremely expensive, and they also finance a robust and politically powerful health care industry, which means lowering prices will always be hard. For a typical angioplasty, a procedure that opens a blocked blood vessel to the heart, the average U.S. price is $32,200, compared with $6,400 in the Netherlands, or $7,400 in Switzerland, the survey finds. A typical M.R.I. scan costs $1,420 in the United States, but around $450 in Britain. An injection of Herceptin, an important breast cancer treatment, costs $211 in the United States, compared with $44 in South Africa. These examples aren't outliers. Researchers at Harvard conducted an exhaustive study last year of things that make health systems in developed countries different from one another. The clear finding of those researchers was that it's this huge gap in prices ... that helps explain why the United States is such an expensive place to be sick.
Note: For more along these lines, see concise summaries of deeply revealing news articles on health from reliable major media sources.
European criticism of the World Health Organization's handling of the H1N1 pandemic intensified ... with the release of two reports that accused the agency of exaggerating the threat posed by the virus and failing to disclose possible influence by the pharmaceutical industry on its recommendations for how countries should respond. The WHO's response caused widespread, unnecessary fear and prompted countries around the world to waste millions of dollars. At the same time, the Geneva-based arm of the United Nations relied on advice from experts with ties to drug makers in developing the guidelines it used to encourage countries to stockpile millions of doses of antiviral medications. The first report ... came from the Social, Health and Family Affairs Committee of the Parliamentary Assembly of the Council of Europe, which launched an investigation in response to allegations that the WHO's response to the pandemic was influenced by drug companies that make antiviral drugs and vaccines. The second report, a joint investigation by the [British Medical Journal] and the Bureau of Investigative Journalism ... criticized 2004 guidelines the WHO developed based in part on the advice of three experts who received consulting fees from the two leading manufacturers of antiviral drugs used against the virus, Roche and GlaxoSmithKline.
Note: Explore extensive, eye-opening coverage from reliable sources revealing how the swine and avian flu "pandemics" were designed for corporate profit.
As the 2018 elections approach, the American intelligence community is issuing increasingly dire warnings about potential interference from Russia and other countries. D.H.S. has now conducted remote-scanning and on-site assessments of state and county election systems. These [measures] don't address core vulnerabilities in voting machines or the systems used to program them. And they ignore the fact that many voting machines that elections officials insist are disconnected from the internet – and therefore beyond the reach of hackers – are in fact accessible by way of the modems they use to transmit vote totals on election night. Add to this the fact that states don't conduct robust postelection audits ... and there's a good chance we simply won't know if someone has altered the digital votes in the next election. How did our election system get so vulnerable, and why haven't officials tried harder to fix it? The answer, ultimately, comes down to politics and money: The voting machines are made by well-connected private companies that wield immense control over their proprietary software, often fighting vigorously in court to prevent anyone from examining it when things go awry. The stakes are high. But the focus on Russia, or any would-be election manipulators, ignores the underlying issue – the myriad vulnerabilities that riddle the system and the ill-considered decisions that got us here.
Note: Why is it that the U.S. government is not allowed to have oversight over the companies that build and maintain voting machines and databases? What if one or more of them is bought off by a foreign or event domestic interest? Isn't this crazy? The major media have severely neglected reporting on elections manipulations that have been going on for many decades. For undeniable evidence of this, see our Elections Information Center.
Facebook wants to get up close and personal with its users after a patent was revealed detailing a desire to secretly watch users through their webcam or smartphone camera, spying on your mood in order to sell you tailored content or advertisements. The purpose behind the invasive idea is to analyse people through the camera in real time while they browse online and if it recognises you looking happy, bored or sad, it would deliver an advert fitting your emotion. If you were forlorn, for example, it would be able to serve an ad to perk you up, or know what products you had previously looked at online and put them under your nose at just the right time. The social network has filed several patents over the years on emotion-based technology but this, based on 'passive imaging data' is perhaps the most unnerving, considering it would take control of cameras that weren't even switched on by the user. As described by CB Insights: "This patent proposes capturing images of the user through smartphone or laptop cameras, even when the user is not actively using the camera. By visually tracking a user's facial expression, Facebook aims to monitor the user's emotional reactions to different types of content." Other patents listed by Facebook include a text messaging platform to detect a user's mood by measuring how hard and fast they were typing, then augment the message format, such as adding emojis or changing the font size, to match their emotion.
Wells Fargo Bank, one of the nation's largest banks, has been hit with $185 million in civil penalties for secretly opening millions of unauthorized deposit and credit card accounts that harmed customers, federal and state officials said Thursday. Employees of Wells Fargo (WFC) boosted sales figures by covertly opening the accounts and funding them by transferring money from customers' authorized accounts without permission, the Consumer Financial Protection Bureau, Office of the Comptroller of the Currency and Los Angeles city officials said. An analysis by the San Francisco-headquartered bank found that its employees opened more than two million deposit and credit card accounts that may not have been authorized by consumers. Many of the transfers ran up fees or other charges for the customers, even as they helped employees make incentive goals. The bank agreed to pay full restitution to all victims and a $100 million fine to the Consumer Financial Protection Bureau's civil penalty fund - the largest in the regulator's five-year operating history. Wells Fargo will pay a separate $35 million penalty to the Office of the Comptroller of the Currency. Additionally, Wells Fargo said it terminated approximately 5,300 employees and managers over a five-year period for their involvement with the unauthorized accounts.
Note: No Wells Fargo executives have been held responsible for this bank's institutionalized breach of customer trust. Do you think these actions were taken without approval from at least one executive? For more along these lines, see concise summaries of deeply revealing banking corruption news articles from reliable major media sources.
Important Note: Explore our full index to revealing excerpts of key major media news articles on several dozen engaging topics. And don't miss amazing excerpts from 20 of the most revealing news articles ever published.